Cetera Investment Advisers Halozyme Therapeutics, Inc. Transaction History
Cetera Investment Advisers
- $55.9 Billion
- Q2 2025
A detailed history of Cetera Investment Advisers transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 45,954 shares of HALO stock, worth $3.14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,954
Previous 45,169
1.74%
Holding current value
$3.14 Million
Previous $2.88 Million
17.07%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding HALO
# of Institutions
637Shares Held
128MCall Options Held
408KPut Options Held
384K-
Black Rock Inc. New York, NY17.6MShares$1.21 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$795 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$406 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$237 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$232 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.53B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...